Efficacy of direct-acting antiviral treatment for chronic hepatitis C:A single hospital experience

• 作者: Masazumi Ogawa Natsuko Nakazaki Rena Kaneko Risa Omori Yuichiro Yano Yuzuru Sato
• 来源期刊: 世界肝病学杂志：英文版（电子版）
• 学科: 医学
• 关键词: Resistance-associated SUBSTITUTIONS Directacting ANTIVIRALS SUSTAINED VIRAL response HEPATITIS C
• 年，卷（期）: 2018,（1）
• 页码范围: 88-94
• 页数: 7页
• 分类号: R

摘要

AIM To evaluate the efficacy of direct-acting antivirals(DAAs)in Kanto Rosai Hospital.METHODS All patients with hepatitis C virus(HCV)who underwent DAA prescription were enrolled in this study.The present study was a single center retrospective analysis using patients infected with HCV genotype 1 or 2.Resistance analysis was performed by using direct sequencing and cycleave PCR in genotype 1 patients treated with interferon(IFN)-free DAA.The primary endpoint was sustained virologic response at 12 wk after therapy(SVR12).RESULTS A total of 117 patients participated in the study,including 135 with genotype 1 and 42 with genotype 2.Of the 135 patients with genotype 1,16 received protease inhibitor+IFN+ribavirin and all achieved SVR.Of the 119 patients who received IFN-free DAA(in different combinations),102 achieved SVR and 9 failed(7/9 were on daclatasvir/asunaprevir and 2/9 on ledipasvir/sofosbuvir).Efficacy analysis was done only for 43 patients who received daclatasvir/asunaprevir.From this analysis,Y93 resistance-associated substitutions were significantly correlated with SVR.CONCLUSION The SVR rate was 98%for genotype 1 and 100%for genotype 2.However,caution is needed for HCV NS5A resistance-associated substitutions that are selected by HCV NS5A inhibitors because cerebrovascular adverse events are induced by some DAA drugs.